Abstracts cardiac (often sudden) death. The use of highly purified omega-3 polyunsaturated fatty acids (n-3 PUFAs) in addition to standard secondary prevention after MI results in a significant reduction in risk of sudden death. OBJECTIVE: To assess the cost-effectiveness of adding n-3 PUFAs to the current secondary prevention treatment after acute MI in five countries (Australia, Belgium, Canada, Germany, Poland) . METHODS: Based on the clinical outcomes of GISSI-Prevenzione (MI, stroke, revascularisation rate and mortality), a decision model was built in DataProTM. The implications of adding n-3 PUFAs to standard treatment in patients with a recent history of MI were analysed from the health care payer's perspective. The time horizon was 3.5 years (identical to GISSI-Prevenzione). Event costs were based on literature data. Life expectancy data for survivors of cardiac disease were obtained from the Saskatchewan database and country-adjusted. Results are expressed as extra cost (€) per life year gained (LYG). Country-specific discounting was applied to costs and effects. RESULTS: Treatment with n-3 PUFAs yielded between 0.265 (Poland) and 0.289 (Canada) LYG, at an additional cost of 823€ (Canada) to 1479€ (Belgium). The incremental cost-effectiveness ratio (ICER) varied between 2850€ (Canada) and 5154€ (Belgium) per LYG. Sensitivity analyses on effectiveness, cost of complications and discounting proved the robustness of the results. A second order Monte Carlo simulation based on the 95% CIs obtained from GISSI showed that n-3 PUFAs are cost-effective in more than 99% of patients (threshold 20,000€/LYG). Including costs incurred during LYG considerably increased total costs, but had no impact on the ICER-based treatment recommendation. CONCLUSIONS: Adding highly purified n-3 PUFAs to standard treatment in the secondary prevention after MI appears to be cost-effective in the five countries studied. 2 Pfizer Pharma GmbH, Karlsruhe, Germany OBJECTIVE: One of the most serious and frequent consequences of acute myocardial infarction is heart failure, which has moved into the focus of public health care in the last few years. The presented modeling determines the epidemiological and health-economic disease burden of post-acute myocardial infarction heart failure in Germany. METHODS: Basis for the concept was a literature review of relevant publications since 1990. The incidence of post-acute myocardial infarction heart failure was estimated for two scenarios and, with the help of a Markov model, the course of the disease and the associated use of resources over a period of nine years was calculated. Subsequently, the annual cost of all prevalent cases was determined. RESULTS: The calculation of the incidence in Germany varies between 50,000 (best case scenario) and 90,000 (worst case scenario) per year. These patients cause total costs of 1.4-2.5 billion euro during the selected observation period (the portion of direct costs is approx. 55 %). The prevalence per year is estimated to be 250,000 to 450,000. Per year these patients cause a financial burden of approximately 0.9-1.6 billion Euros. The majority is due to hospital treatment (0.3-0.5 billion Euros) and the loss of productivity due to premature mortality (0.2-0.4 billion Euros). Apart from the rateable monetary strain, it has to be assumed that after the manifestation of heart failure the quality of life for these patients is reduced by about 50% compared to that of the normal population at a comparable age. CONCLUSION: In light of the heavy financial burden-in particular due to hospital treatment and loss of productivityfollowing the manifestation of heart failure, an early and effective therapy of the initial myocardial infarction is essential. If heart insufficiency nevertheless develops following myocardial infarction, optimum secondary preventive strategies are necessary. 
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